GlassScriptPhysician profile
Jon R Dvorak
NPI 1205828241
$212,108.06
in general payments reported to CMS, 2019-2025
27 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $153 · 2021: $18K · 2022: $70K · 2023: $74K · 2024: $33K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $103K · Travel and Lodging: $15K · Food and Beverage: $5,543 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,025.00 |
| Travel and Lodging | $15,248.04 |
| Food and Beverage | $5,542.63 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $209,125.58 | 2019-2025 | Bexsero, Penmenvy, Hiberix |
| Merck Sharp & Dohme LLC | $510.46 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Pfizer INC. | $403.32 | 2019-2025 | |
| Corium, LLC | $363.32 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $289.16 | 2019-2024 | Jornay Pm |
| Kaleo, INC. | $277.50 | 2019-2024 | Auvi-Q |
| Neos Therapeutics, LP | $144.64 | 2021-2024 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Sanofi Pasteur INC. | $130.51 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.23 | 2019-2022 | |
| Tris Pharma INC | $120.63 | 2022-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $112.38 | 2022-2025 | Qelbree, Qelbree |
| Phadia US INC. | $90.67 | 2019-2024 | Immunocap |
| Genzyme Corporation | $56.93 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $39.96 | 2020-2024 | Exparel, Iovera, Zilretta |
| Seqirus USA INC | $35.20 | 2024-2025 | Flucelvax, Fluad |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $33.72 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $33.37 | 2024-2025 | Relexxii |
| Avion Pharmaceuticals | $31.15 | 2023 | Methylphenidate Hydrochloride |
| Cipher Pharmaceuticals US LLC | $28.16 | 2025 | Natroba, Spinosad |
| Adlon Therapeutics L.P. | $25.11 | 2019-2020 | |
| Sobi, INC | $24.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.69 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.79 | 2024 | Flumist Quadrivalent |
| Aytu Biopharma, INC. | $19.35 | 2024 | Karbinal |
| Roche Diagnostics Corporation | $18.64 | 2019 | |
| Mission Pharmacal Company | $16.25 | 2019 | |
| Novo Nordisk INC | $15.81 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Dvorak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.